These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 33192668)

  • 21. Duloxetine for management of stress urinary incontinence.
    Guay DR
    Am J Geriatr Pharmacother; 2005 Mar; 3(1):25-38. PubMed ID: 16089245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective.
    Liu X; Cui Z; Niu L; Faries DE; Ball T; Johnstone B
    Clin Ther; 2011 Nov; 33(11):1726-38. PubMed ID: 22019345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
    Cowen PJ; Ogilvie AD; Gama J
    Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duloxetine: a review of its safety and efficacy in the management of fibromyalgia syndrome.
    Smith HS; Bracken D; Smith JM
    J Cent Nerv Syst Dis; 2010; 2():57-72. PubMed ID: 23861632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists.
    Alvarez-Mon MA; García-Montero C; Fraile-Martinez O; Quintero J; Fernandez-Rojo S; Mora F; Gutiérrez-Rojas L; Molina-Ruiz RM; Lahera G; Álvarez-Mon M; Ortega MA
    Brain Sci; 2023 Feb; 13(2):. PubMed ID: 36831876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials.
    Pangallo BA; Zhang Q; Desaiah D; Perahia DG; Detke MJ; Kennedy SH
    Curr Med Res Opin; 2010 Nov; 26(11):2643-51. PubMed ID: 20932222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duloxetine treatment adherence across mental health and chronic pain conditions.
    Able SL; Cui Z; Shen W
    Clinicoecon Outcomes Res; 2014; 6():75-81. PubMed ID: 24596469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.
    Detke MJ; Lu Y; Goldstein DJ; McNamara RK; Demitrack MA
    J Psychiatr Res; 2002; 36(6):383-90. PubMed ID: 12393307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duloxetine for the treatment of post-prostatectomy stress urinary incontinence.
    Neff D; Guise A; Guralnick ML; Langenstroer P; See WA; Jacobsohn KM; O'Connor RC
    Can Urol Assoc J; 2013; 7(5-6):E260-2. PubMed ID: 23766826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians.
    Koponen H; Allgulander C; Erickson J; Dunayevich E; Pritchett Y; Detke MJ; Ball SG; Russell JM
    Prim Care Companion J Clin Psychiatry; 2007; 9(2):100-7. PubMed ID: 17607331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duloxetine in the treatment of stress urinary incontinence.
    Jost WH; Marsalek P
    Ther Clin Risk Manag; 2005 Dec; 1(4):259-64. PubMed ID: 18360568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis.
    Li X; Zhu L; Zhou C; Liu J; Du H; Wang C; Fang S
    PLoS One; 2018; 13(3):e0194501. PubMed ID: 29558528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duloxetine in the treatment of generalized anxiety disorder.
    Kornstein SG; Russell JM; Spann ME; Crits-Christoph P; Ball SG
    Expert Rev Neurother; 2009 Feb; 9(2):155-65. PubMed ID: 19210191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duloxetine in the treatment of major depression and other psychiatric disorders.
    Blanco C; Okuda M; Rosenthal H; Lewis-Fernandez R
    Expert Rev Clin Pharmacol; 2008 Mar; 1(2):195-205. PubMed ID: 24422645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.